Ćeriman Krstić Vesna, Samardžić Natalija, Gajić Milija, Savić Milan, Šeha Biljana, Roksandić Milenković Marina, Jovanović Dragana
Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Clinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
Curr Issues Mol Biol. 2024 Nov 24;46(12):13443-13455. doi: 10.3390/cimb46120802.
Lung cancer represents the most common cause of cancer-related death. Patients with non-small cell lung cancer (NSCLC) and liver metastases have worse prognosis, with an overall survival (OS) from three to six months. The majority of them have a poor response to chemotherapy, and the data are controversial regarding the response to immunotherapy. This could be because the liver is considered to be an immune-tolerant organ, which is characterized by T-cell anergy and immunosuppressive signals. This review evaluates current treatment options for patients with NSCLC and liver metastases. Combination therapies might be a better treatment option for this subgroup of patients. The addition of radiotherapy to immunotherapy could also be an option in selected patients. The resection of single liver metastasis should also be considered.
肺癌是癌症相关死亡的最常见原因。非小细胞肺癌（NSCLC）伴肝转移的患者预后较差，总生存期（OS）为三到六个月。他们中的大多数对化疗反应不佳，关于免疫治疗的反应数据存在争议。这可能是因为肝脏被认为是一个免疫耐受器官，其特征是T细胞无反应性和免疫抑制信号。本综述评估了NSCLC伴肝转移患者的当前治疗选择。联合治疗可能是该亚组患者更好的治疗选择。对选定患者而言，在免疫治疗中加入放疗也可能是一种选择。也应考虑切除单个肝转移灶。
